GARIN5A: A Potential Drug Target and Biomarker (G112703)

Target Name: GARIN5A

NCBI ID: G112703

GARIN5A

GARIN5A: A Potential Drug Target and Biomarker

GARIN5A is a protein that belongs to the family of FAM71E1 proteins, which are known for their role in various cellular processes. This protein has been identified as a potential drug target and biomarker due to its unique structure and its involvement in several diseases.

GARIN5A is a 21-kDa protein that is expressed in various tissues, including the brain, heart, liver, and pancreas. It is characterized by a N-terminus that contains a characteristic Rossmann domain, which is known for its ability to interact with other proteins. The C-terminus of GARIN5A contains a unique farnesylated cysteine residue, which is involved in the protein's stability and localization in the cell.

GARIN5A is involved in several cellular processes that are crucial for human health, including cell signaling, inflammation, and metabolism. One of the most significant functions of GARIN5A is its role in the regulation of mitochondrial function. GARIN5A has been shown to interact with the protein known as Mitofusin, which is a transmembrane protein that is involved in mitochondrial fusion. This interaction between GARIN5A and Mitofusin suggests that GARIN5A may play a role in regulating mitochondrial fusion and may be a potential drug target for diseases related to mitochondrial dysfunction, such as cancer, neurodegenerative diseases, and cardiovascular diseases.

GARIN5A is also involved in the regulation of inflammation. Inflammation is a critical immune response that helps the body heal from injuries and illnesses. However, prolonged inflammation can lead to a host of diseases, including cancer, autoimmune diseases, and cardiovascular diseases. GARIN5A has been shown to play a role in the regulation of inflammation by interacting with the protein known as NF-kappa-B. This interaction between GARIN5A and NF-kappa-B suggests that GARIN5A may be a potential biomarker for inflammation-related diseases.

GARIN5A is also involved in the regulation of cellular metabolism. Metabolism is the process by which cells convert energy and nutrients into the components necessary for growth and maintenance. GARIN5A has been shown to interact with several enzymes involved in cellular metabolism, including the enzyme known as Pyruvate Carrier. This interaction between GARIN5A and Pyruvate Carrier suggests that GARIN5A may be a potential drug target for diseases related to cellular metabolism, such as obesity, diabetes, and cancer.

In conclusion, GARIN5A is a protein that has been identified as a potential drug target and biomarker due to its unique structure and its involvement in several diseases. Its involvement in the regulation of mitochondrial function, inflammation, and cellular metabolism suggests that GARIN5A may be a valuable tool for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of GARIN5A in human health and to determine its potential as a drug target and biomarker.

Protein Name: Golgi Associated RAB2 Interactor 5A

Functions: RAB2B effector protein which promotes cytosolic DNA-induced innate immune responses. Regulates IFN responses against DNA viruses by regulating the CGAS-STING signaling axis

The "GARIN5A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GARIN5A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets